RA CAPITAL MANAGEMENT, L.P. purchased $456K of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 45,768 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.96 ($9.93–$9.99, $0.46M total) across 2 trades over 2026-07-29 to 2026-07-31.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 31, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
low confidence
Mentioned
$ARTV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The newest disclosed fact is the open-market purchase size, price range, and post-transaction share count. It does not include any operational or financial updates for Artiva.

02

Market read

Traders may note the disclosed buy as a positioning signal, but there is no accompanying catalyst that would justify a high-conviction trade.

03

What to watch

Indirect holdings and 10b5-1 status are not provided as a plan (explicitly says no pre-arranged 10b5-1), but without context on total position changes or investment mandate, the signal strength is uncertain.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-31, covering purchases from 2026-07-29 to 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics (ARTV), reported by RA Capital Management, L.P. as a 10% owner with indirect holdings.

Company-level read

Ticker impact

$ARTVNeutralLow confidence
Context

RA Capital Management filed a Form 4 showing an indirect open-market purchase of 45,768 shares of Artiva Biotherapeutics at about $9.93 to $9.99.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst beyond positioning signal.

Evidence & confidence

The filing is a Form 4 for an indirect holding by a 10% owner, with no accompanying guidance, trial, deal, or regulatory event. Such transactions often have modest market impact unless tied to a broader corporate catalyst.

Market effects

Minimal; single-company Form 4 activity does not materially change biotech sector fundamentals.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine rebalancing or pre-existing exposure rather than a new bullish thesis, so price reaction may be muted.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (ARTV).

  • RA Capital Management, L.P.

    10% owner reporting an indirect open-market purchase of ARTV shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.